Search

Displaying results 5131 - 5140 of 7058 in total
  1. Drug

    TA-CIN

    go.drugbank.com/drugs/DB05809
    Investigational

    TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.

    Synonyms: TA-CIN
  2. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours.

  3. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

  4. Drug

    Calanolide A

    go.drugbank.com/drugs/DB04886
    Investigational

    Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. … A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.

    Synonyms: Calanolide A, (+)-calanolide A
  5. Drug

    Equilin

    go.drugbank.com/drugs/DB02187
    Experimental

    It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.

  6. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  7. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  8. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance ...

  9. Drug

    BL-1020

    go.drugbank.com/drugs/DB05687
    Investigational

    BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).

  10. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.